| Assay ID | Title | Year | Journal | Article |
|---|
| AID1593464 | Selectivity ratio of EC50 for agonist activity at human D2L receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP accumulation to EC50 for agonist activity at human D4 receptor expressed in CHOK1 cells assessed as inhibition o | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593455 | Selectivity ratio of Ki for displacement of [3H](R)-(+)-7-OH-DPAT from human D3 receptor expressed in HEK293 cell membranes to Ki for displacement of [3H](R)-(+)-7-OH-DPAT from human D4.4 receptor expressed in HEK293 cell membranes | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593469 | Antagonist activity at human D2L receptor expressed in CHOK1 cells assessed as inhibition of dopamine-induced beta-arrestin recruitment measured after 90 mins by luminescence assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593482 | Agonist activity at D1 receptor (unknown origin) stably expressed in CHOK1 cells assessed as induction of beta-arrestin recruitment measured after 90 mins by luminescence assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1851871 | Cytotoxicity against human U-251 cells assessed as reduction in cell viability at 5 to 50 uM incubated for 24 hrs by MTS assay | | | |
| AID1593460 | Agonist activity at human D4 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by Eu-cAMP tracer based TR-FRET assay relative to dopamine | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593449 | Selectivity ratio of Ki for displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes to Ki for displacement of [3H]N-methylspiperone from human D4.4 receptor expressed in HEK293 cell membranes | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593450 | Selectivity ratio of Ki for displacement of [3H]N-methylspiperone from human D3 receptor expressed in HEK293 cell membranes to Ki for displacement of [3H]N-methylspiperone from human D4.4 receptor expressed in HEK293 cell membranes | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID274440 | Agonist activity at human D4.4 receptor in HEK293 cells co-expressing Galphaqo5 by FLIPR with relative to dopamine | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
| Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. |
| AID1593466 | Agonist activity at human D2L receptor expressed in CHOK1 cells assessed as induction of beta-arrestin recruitment measured after 90 mins by luminescence assay relative to control | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593467 | Agonist activity at human D2L receptor expressed in CHOK1 cells assessed as induction of beta-arrestin recruitment measured after 90 mins by luminescence assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593463 | Antagonist activity at human D4 receptor expressed in CHOK1 cells assessed as suppression of dopamine-induced inhibition of forskolin-stimulated cAMP accumulation measured after 30 mins by Eu-cAMP tracer based TR-FRET assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593457 | Agonist activity at human D2L receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by Eu-cAMP tracer based TR-FRET assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593451 | Displacement of [3H](R)-(+)-7-OH-DPAT from human D2L receptor expressed in HEK293 cell membranes measured after 90 mins by scintillation counting method | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593485 | Antagonist activity at D5 receptor (unknown origin) stably expressed in CHOK1 cells assessed as inhibition of dopamine-induced beta-arrestin recruitment measured after 90 mins by luminescence assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593448 | Displacement of [3H]N-methylspiperone from human D4.4 receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593484 | Antagonist activity at D1 receptor (unknown origin) stably expressed in CHOK1 cells assessed as inhibition of dopamine-induced beta-arrestin recruitment measured after 90 mins by luminescence assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID274457 | Displacement of [3H]A369508 from human D4 receptor expressed in HEK293 cell membrane | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
| Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. |
| AID1593459 | Antagonist activity at human D2L receptor expressed in CHOK1 cells assessed as suppression of dopamine-induced inhibition of forskolin-stimulated cAMP accumulation measured after 30 mins by Eu-cAMP tracer based TR-FRET assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593475 | Agonist activity at human D4 receptor expressed in CHOK1 cells assessed as induction of beta-arrestin recruitment measured after 90 mins by luminescence assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593480 | Selectivity ratio of EC50 for agonist activity at human D3 receptor expressed in CHOK1 cells assessed as induction of beta-arrestin recruitment to EC50 for agonist activity at human D4 receptor expressed in CHOK1 cells assessed as induction of beta-arrest | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID274471 | Bioavailability in Sprague-Dawley rat at 1 mg/kg, sc | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
| Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. |
| AID1593454 | Selectivity ratio of Ki for displacement of [3H](R)-(+)-7-OH-DPAT from human D2L receptor expressed in HEK293 cell membranes to Ki for displacement of [3H](R)-(+)-7-OH-DPAT from human D4.4 receptor expressed in HEK293 cell membranes | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593478 | Selectivity ratio of EC50 for agonist activity at human D2L receptor expressed in CHOK1 cells assessed as induction of beta-arrestin recruitment to EC50 for agonist activity at human D4 receptor expressed in CHOK1 cells assessed as induction of beta-arres | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593462 | Antagonist activity at human D4 receptor expressed in CHOK1 cells assessed as suppression of dopamine-induced inhibition of forskolin-stimulated cAMP accumulation measured after 30 mins by Eu-cAMP tracer based TR-FRET assay relative to dopamine | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593447 | Displacement of [3H]N-methylspiperone from human D3 receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593473 | Antagonist activity at human D3 receptor expressed in CHOK1 cells assessed as inhibition of dopamine-induced beta-arrestin recruitment measured after 90 mins by luminescence assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID274473 | Half life in Sprague-Dawley rat at 1 mg/kg, sc | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
| Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. |
| AID274467 | Proerectile activity in rat measured as incidence of penile erection at 0.1 umol/kg, sc | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
| Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. |
| AID1593483 | Agonist activity at D5 receptor (unknown origin) stably expressed in CHOK1 cells assessed as induction of beta-arrestin recruitment measured after 90 mins by luminescence assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1851859 | Cytotoxicity against human T98G cells assessed as reduction in cell viability at 5 to 50 uM incubated for 24 hrs by MTS assay | | | |
| AID1593476 | Antagonist activity at human D4 receptor expressed in CHOK1 cells assessed as inhibition of dopamine-induced beta-arrestin recruitment measured after 90 mins by luminescence assay relative to control | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593471 | Agonist activity at human D3 receptor expressed in CHOK1 cells assessed as induction of beta-arrestin recruitment measured after 90 mins by luminescence assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593452 | Displacement of [3H](R)-(+)-7-OH-DPAT from human D3 receptor expressed in HEK293 cell membranes measured after 90 mins by scintillation counting method | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593477 | Antagonist activity at human D4 receptor expressed in CHOK1 cells assessed as inhibition of dopamine-induced beta-arrestin recruitment measured after 90 mins by luminescence assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593453 | Displacement of [3H](R)-(+)-7-OH-DPAT from human D4.4 receptor expressed in HEK293 cell membranes measured after 90 mins by scintillation counting method | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1851872 | Cytotoxicity against human GSC#83 cells assessed as reduction in cell viability at 5 to 50 uM incubated for 24 hrs by MTS assay | | | |
| AID1593446 | Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593472 | Antagonist activity at human D3 receptor expressed in CHOK1 cells assessed as inhibition of dopamine-induced beta-arrestin recruitment measured after 90 mins by luminescence assay relative to control | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593481 | Selectivity ratio of IC50 for antagonist activity at human D3 receptor expressed in CHOK1 cells assessed as inhibition of dopamine-induced beta-arrestin recruitment to IC50 for antagonist activity at human D4 receptor expressed in CHOK1 cells assessed as | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593470 | Agonist activity at human D3 receptor expressed in CHOK1 cells assessed as induction of beta-arrestin recruitment measured after 90 mins by luminescence assay relative to control | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID274474 | Half life in Sprague-Dawley rat at 1 mg/kg, po | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
| Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. |
| AID274437 | Agonist activity at human D4.4 receptor in HEK293 cells coexpressing G-alpha-qo5 by FLIPR | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
| Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. |
| AID1593456 | Agonist activity at human D2L receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by Eu-cAMP tracer based TR-FRET assay relative to dopamine | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID274455 | Activity at human D4.4 receptor in HEK293 cells co-expressing Galphaqo5 by FLIPR | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
| Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. |
| AID1593479 | Selectivity ratio of IC50 for antagonist activity at human D2L receptor expressed in CHOK1 cells assessed as inhibition of dopamine-induced beta-arrestin recruitment to IC50 for antagonist activity at human D4 receptor expressed in CHOK1 cells assessed as | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593458 | Antagonist activity at human D2L receptor expressed in CHOK1 cells assessed as suppression of dopamine-induced inhibition of forskolin-stimulated cAMP accumulation measured after 30 mins by Eu-cAMP tracer based TR-FRET assay relative to dopamine | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593465 | Selectivity ratio of IC50 for antagonist activity at human D2L receptor expressed in CHOK1 cells assessed as suppression of dopamine-induced inhibition of forskolin-stimulated cAMP accumulation to IC50 for antagonist activity at human D4 receptor expresse | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593461 | Agonist activity at human D4 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by Eu-cAMP tracer based TR-FRET assay | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1593468 | Antagonist activity at human D2L receptor expressed in CHOK1 cells assessed as inhibition of dopamine-induced beta-arrestin recruitment measured after 90 mins by luminescence assay relative to control | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID274472 | Bioavailability in Sprague-Dawley rat at 1 mg/kg, po | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
| Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. |
| AID274456 | Displacement of [125I]7-OH-PIPAT from human D2L receptor expressed in HEK293 cell membrane | 2006 | Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
| Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. |
| AID1593474 | Agonist activity at human D4 receptor expressed in CHOK1 cells assessed as induction of beta-arrestin recruitment measured after 90 mins by luminescence assay relative to control | 2019 | Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
| Dopamine D |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347024 | Rat D4 receptor (Dopamine receptors) | 2005 | Pharmacology, biochemistry, and behavior, Sep, Volume: 82, Issue:1
| A-412997 is a selective dopamine D4 receptor agonist in rats. |
| AID1345814 | Human D4 receptor (Dopamine receptors) | 2005 | Pharmacology, biochemistry, and behavior, Sep, Volume: 82, Issue:1
| A-412997 is a selective dopamine D4 receptor agonist in rats. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |